mesalamine has been researched along with ajm300 in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Hibi, T; Hirai, F; Ishida, T; Ishiguro, Y; Kajioka, T; Kanke, K; Kishida, S; Kobayashi, K; Matsuoka, K; Miura, Y; Mizusawa, H; Nakajima, K; Ohmori, T; Ohta, A; Watanabe, K; Watanabe, M | 1 |
1 trial(s) available for mesalamine and ajm300
Article | Year |
---|---|
AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
Topics: Colitis, Ulcerative; Humans; Induction Chemotherapy; Integrin alpha4; Mesalamine; Nasopharyngitis; Phenylalanine; Quinazolinones; Treatment Outcome | 2022 |